Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Randomized Study of Belzutifan (MK-6482) Versus Everolimus in Advanced Renal Cell Carcinoma After Prior PD-1/L1 and VEGF-Targeted Therapies
jRCT2080225166Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of belzutifan in renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Started Apr 2020; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080225166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225166.